ArticleMagyar onkologia2024
[Molecular pathology of lung adenocarcinomas, EGFR T790M resistance mutation study].
Article in Magyar onkologia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic value of baselineFrontiers in nuclear medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimIn our institute, we have been testing EGFR T790M resistance mutations since 2019, which is the most common resistance mutation that develops during first-line, second- line EGFR TKI treatment of EGFR mutant lung adenocarcinomas. The importance of this study is that the identification of this mutation will allow the use of an effective third-generation TKI. In this article, we report on studies from January 2022 to August 2024, compared with our results from the 2019-2021 period.
methods380, predominantly blood samples from 222 patients were tested during the present period using Super- ARMS EGFR Mutation Detection Kit (AmoyDx).
resultsEGFR mutations were identified in 57% of all samples in the primary tumours, with a 38.3% frequency of T790M mutation.
conclusionsOur results were similar to the previous period. The number of rebiopsies was essentially unchanged compared to the 2019-2021 period, which may be the main reason why we were able to identify the mutation in a lower percentage compared to the T790M hit rate described in the literature.
Indexed as
Identifiers
39657044PMC11841701What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.